VVOS Vivos Therapeutics, Inc
Price Chart
Executive Summary
Vivos Therapeutics closed a $2.25 million private placement with V-Co Investors 3 LLC, an affiliate of New Seneca Partners, including the conversion of a $1.4 million bridge note. The funds will be used for working capital as the company executes its shift toward medical practice affiliations and aims for breakeven cash flow by end of 2026.
Key Financial Metrics
Actionable Insight
Monitor for follow-on dilution risk and track progress toward breakeven cash flow by year-end; insider buying suggests confidence, but small cap and repeated financings indicate high execution risk.
Key Facts
- Vivos Therapeutics (VVOS) raised $2.25 million in a private placement closed on March 31, 2026.
- Proceeds include conversion of a $1.4 million bridge note (pre-OID), with total gross proceeds excluding a $140,000 original issue discount.
- Investor V-Co 3 received common stock, a pre-funded warrant, and two common stock purchase warrants (2-year and 5-year), all exercisable at $1.09 per share.
- Purchase price per unit was $1.34, set to comply with Nasdaq listing rules.
- Since 2024, Seneca affiliates have invested $13.4 million in Vivos.
- Proceeds will be used for general working capital; company aims for breakeven operating cash flow by end of 2026.
Financial Impact
$2.25 million gross proceeds, dilutive financing with warrants issued at $1.09 strike price
Risk Factors
- Dilution from issuance of common stock and multiple warrants exercisable at $1.09
- Failure to achieve breakeven cash flow by end of 2026 as targeted
- Dependence on continued support from a single investor group (Seneca affiliates)
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3269171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
1d ago
|
8-K
| $0.7600 awaiting T+5 | awaiting T+5 | — | $0.7002 (+7.87%) |
|
May 20, 2026
20d ago
|
Press Release
| $0.5850 $0.6700 | ▲ +14.53% | ▲ +12.93% | $0.7002 (+19.69%) |
|
Apr 15, 2026
7w ago
|
8-K
| $1.09 $0.8960 | ▼ −17.80% | ▼ −18.78% | $0.7002 (−35.76%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $1.09 $0.8960 | ▲ +17.80% | ▲ +18.78% | $0.7002 (+35.76%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $1.47 $1.03 | ▲ +29.93% | ▲ +31.57% | $0.7002 (+52.37%) |
|
Apr 7, 2026
9w ago
|
Press Release
| $1.24 $1.35 | ▲ +8.87% | ▲ +3.54% | $0.7002 (−43.53%) |
|
Apr 3, 2026
9w ago
|
8-K
| $1.31 $1.22 | ▲ +6.87% | ▲ +11.00% | $0.7002 (+46.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access